SLDB Logo

Solid Biosciences Inc. (SLDB) 

NASDAQ$5.09
Market Cap
$394.44M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
16 of 924
Rank in Industry
12 of 527

SLDB Insider Trading Activity

SLDB Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$26,107,606524
Sells
$298,6891676

Related Transactions

PERCEPTIVE ADVISORS LLC1$20.15M0$0$20.15M
Bain Capital Life Sciences Investors, LLC10 percent owner1$4.03M0$0$4.03M
Adage Capital Management, L.P.10 percent owner1$1.91M0$0$1.91M
Kahn Claredirector2$18,3660$0$18,366
Ganot Ilandirector0$04$16,547$-16,547
Herzich PaulChief Technology Officer0$02$26,195$-26,195
Tan KevinCFO & Treasurer0$02$28,379$-28,379
Brooks GabrielChief Medical Officer0$02$31,893$-31,893
Hanrahan JessieChief Regulatory Officer0$02$38,015$-38,015
Howton David TChief Operating Officer0$02$50,418$-50,418
Cumbo AlexanderPresident and CEO0$02$107,242$-107,242

About Solid Biosciences Inc.

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one â€¦

Insider Activity of Solid Biosciences Inc.

Over the last 12 months, insiders at Solid Biosciences Inc. have bought $26.11M and sold $298,689 worth of Solid Biosciences Inc. stock.

On average, over the past 5 years, insiders at Solid Biosciences Inc. have bought $35.12M and sold $297,764 worth of stock each year.

Highest buying activity among insiders over the last 12 months: PERCEPTIVE ADVISORS LLC () — $20.15M. Bain Capital Life Sciences Investors, LLC (10 percent owner) — $4.03M. Adage Capital Management, L.P. (10 percent owner) — $1.91M.

The last purchase of 1,860 shares for transaction amount of $9,924 was made by Kahn Clare (director) on 2025‑03‑11.

List of Insider Buy and Sell Transactions, Solid Biosciences Inc.

2025-03-11PurchaseKahn Claredirector
1,860
0.0023%
$5.34$9,924-8.20%
2025-02-19PurchasePERCEPTIVE ADVISORS LLC
5M
9.5155%
$4.03$20.15M-8.74%
2025-02-19PurchaseBain Capital Life Sciences Investors, LLC10 percent owner
1M
1.9031%
$4.03$4.03M-8.74%
2025-02-18PurchaseAdage Capital Management, L.P.10 percent owner
252,545
1.1857%
$7.56$1.91M-9.17%
2025-02-14SaleCumbo AlexanderPresident and CEO
11,365
0.0286%
$3.96$45,005+35.98%
2025-02-14SaleTan KevinCFO & Treasurer
3,164
0.008%
$3.96$12,529+35.98%
2025-02-14SaleHowton David TChief Operating Officer
5,561
0.014%
$3.96$22,022+35.98%
2025-02-14SaleBrooks GabrielChief Medical Officer
3,256
0.0082%
$3.96$12,894+35.98%
2025-02-14SaleHanrahan JessieChief Regulatory Officer
3,079
0.0077%
$3.96$12,193+35.98%
2025-02-14SaleHerzich PaulChief Technology Officer
2,688
0.0068%
$3.96$10,644+35.98%
2025-02-14SaleGanot Ilandirector
1,711
0.0043%
$3.96$6,776+35.98%
2025-01-28SaleGanot Ilandirector
144
0.0003%
$3.11$448+56.63%
2025-01-10SaleTan KevinCFO & Treasurer
4,073
0.0109%
$3.89$15,849-0.54%
2025-01-06SaleGanot Ilandirector
1,056
0.0028%
$4.31$4,551-7.32%
2024-12-03SaleCumbo AlexanderPresident and CEO
11,114
0.0299%
$5.60$62,236-20.46%
2024-12-03SaleHowton David TChief Operating Officer
5,072
0.0136%
$5.60$28,396-20.46%
2024-12-03SaleHanrahan JessieChief Regulatory Officer
4,610
0.0124%
$5.60$25,822-20.46%
2024-12-03SaleHerzich PaulChief Technology Officer
2,777
0.0075%
$5.60$15,551-20.46%
2024-10-21SaleBrooks GabrielChief Medical Officer
2,923
0.0085%
$6.50$19,000-13.23%
2024-06-07PurchaseKahn Claredirector
1,100
0.0027%
$7.67$8,442-27.30%
Total: 70
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
PERCEPTIVE ADVISORS LLC
11833539
15.2705%
$60.23M50<0.0001%
Bain Capital Life Sciences Investors, LLC10 percent owner
5034582
6.4968%
$25.63M10
Adage Capital Management, L.P.10 percent owner
4248084
5.4819%
$21.62M10
Kahn Claredirector
2960
0.0038%
$15,066.4020
RA CAPITAL MANAGEMENT, L.P.
4192216
5.4098%
$21.34M20<0.0001%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$14,527,743
76
38.40%
$447.93M
$84,871,118
57
17.71%
$412.59M
$26,923,982
20
-17.22%
$407.13M
$73,222,926
18
60.19%
$406.4M
$14,865,077
18
-28.56%
$389.16M

SLDB Institutional Investors: Active Positions

Increased Positions51+54.84%4M+10.69%
Decreased Positions37-39.78%3M-9.34%
New Positions16New795,664New
Sold Out Positions18Sold Out1MSold Out
Total Postitions107+15.05%36M+1.35%

SLDB Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Perceptive Advisors Llc$38,608.009.09%6.91M00%2024-12-31
Ra Capital Management, L.P.$24,207.005.7%4.33M00%2024-12-31
Bain Capital Life Sciences Investors, Llc$22,553.005.31%4.03M00%2024-12-31
Siren, L.L.C.$20,957.004.93%3.75M+1M+36.38%2024-12-31
Vestal Point Capital, Lp$15,932.003.75%2.85M+50,000+1.79%2024-12-31
Blackrock, Inc.$10,401.002.45%1.86M+258,414+16.13%2024-12-31
Adage Capital Partners Gp, L.L.C.$9,772.002.3%1.75M-6,075-0.35%2024-12-31
Vanguard Group Inc$7,833.001.84%1.4M+30,207+2.2%2024-12-31
Finepoint Capital Lp$5,373.001.27%961,25100%2024-12-31
Jpmorgan Chase & Co$5,344.001.26%955,932+945,863+9,393.81%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.